New-onset diabetes after renal transplantation

Diabetic Medicine

Volumn 31, Issue 11, 2014, Pages 1284-1292

  Tufton, N ^a   Ahmad, S ^a   Rolfe, C ^a   Rajkariar, R ^a   Byrne, C ^a   Chowdhury, T A ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; HEMOGLOBIN A1C; IMMUNOSUPPRESSIVE AGENT;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CAUSE OF DEATH; CLINICAL EFFECTIVENESS; DIABETES MELLITUS; EPIDEMIOLOGICAL DATA; GRAFT RECIPIENT; GRAFT SURVIVAL; HEPATITIS C; HEREDITY; HUMAN; HYPERGLYCEMIA; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INSULIN RESISTANCE; KIDNEY DISEASE; KIDNEY TRANSPLANTATION; LIFESTYLE MODIFICATION; MORBIDITY; NEW ONSET DIABETES AFTER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATHOGENESIS; PATIENT RISK; PRACTICE GUIDELINE; PREDICTION; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST; SYSTEMATIC REVIEW (TOPIC); WORLD HEALTH ORGANIZATION; ADVERSE EFFECTS; ANIMAL; DIABETES MELLITUS, TYPE 2; POSTOPERATIVE COMPLICATIONS;

ANIMALS; DIABETES MELLITUS, TYPE 2; HUMANS; KIDNEY TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RISK FACTORS;

EID: 84925943032     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12534     Document Type: Review

References (58)

1. Diabetes UK. Diabetes in the UK in 2010: Key Statistics on Diabetes 2011. Available at: http://www.diabetes.org.uk/Documents/Reports/Diabetes_in_the_UK_2010.pdf. Last accessed 11 April 2014.
2. The Renal Association. UK Renal Registry 2009. Nephron Clin Pract 2010;115 (Suppl.1): c1-c370.
3. Starzl TE, Marchioro TL, Rifkind D, Holmes JH, Rowlands DT, Waddell WR. Factors in Successful Renal Transplantation. Surgery 1964; 56: 296-318.
4. Wilkinson A, Davidson J, Dotta F, Home PD, Keown P, Kiberd B et al. Guidelines for the treatment and management of new-onset diabetes after transplantation. Clin Transplant 2005; 19: 291-298.
5. World Health Organisation, 2011. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Abbreviated report of a WHO consultation. WHO Geneva. Available at: http://www.who.int/diabetes/publications/report-hba1c_2011.pdf. Last accessed 11 April 2014.
6. Valderhaug TG, Jenssen T, Hartmann A, Midtvedt K, Holdaas H, Reisaeter AV et al. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. Transplantation 2009; 88: 429-434.
7. Shabir S, Jham S, Harper L, Ball S, Borrows R, Sharif A. Validity of glycated haemoglobin to diagnose new onset diabetes after transplantation. Transpl Int 2013; 26: 315-321.
8. Pham PT, Edling KL, Chakkera HA, Pham PC, Pham PM. Screening strategies and predictive diagnostic tools for the development of new-onset diabetes mellitus after transplantation: an overview. Diabetes Metab Syndr Obes 2012; 5: 379-387.
9. Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: An underdiagnosed phenomenon. Transplantation 2006; 82: 1667-1672.
10. Cosio FG, Kudva Y, van der Velde M, Larson TS, Textor SC, Griffin MD et al. New onset hyperglycemia and diabetes are associated with increased cardiovascular risk after kidney transplantation. Kidney Int 2005; 67: 2415-2421.
11. Yates CJ, Fourlanos S, Colman PG, Cohney SJ. Screening for new-onset diabetes after kidney transplantation: limitations of fasting glucose and advantages of afternoon glucose and glycated hemoglobin. Transplantation 2013; 96: 726-731.
12. Bergrem HA, Valderhaug TG, Hartmann A, Hjelmesaeth J, Leivestad T, Bergrem H et al. Undiagnosed diabetes in kidney transplant candidates: a case-finding strategy. Clin J Am Soc Nephrol 2010; 5: 616-622.
13. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ. Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 2003; 3: 178-185.
14. Chakkera HA, Knowler WC, Devarapalli Y, Weil EJ, Heilman RL, Dueck A et al. Relationship between inpatient hyperglycemia and insulin treatment after kidney transplantation and future new onset diabetes mellitus. Clin J Am Soc Nephrol 2010; 5: 1669-1675.
15. Woodward RS et al. Incidence and cost of new onset diabetes mellitus among U.S. wait-listed and transplanted renal allograft recipients. Am J Transplant 2003; 3: 590-598.
16. First MR, Dhadda S, Croy R, Holman J, Fitzsimmons WE. New-onset diabetes after transplantation (NODAT): an evaluation of definitions in clinical trials. Transplantation 2013; 96: 58-64.
17. Chakkera HA, Weil EJ, Pham PT, Pomeroy J, Knowler WC. Can new-onset diabetes after kidney transplant be prevented? Diabetes Care 2013; 36: 1406-1412.
18. Zelle DM, Corpeleijn E, Deinum J, Stolk RP, Gans RO, Navis G et al. Pancreatic beta-cell dysfunction and risk of new-onset diabetes after kidney transplantation. Diabetes Care 2013; 36: 1926-1932.
19. Hecking M, Haidinger M, Döller D, Werzowa J, Tura A, Zhang J, Tekoglu H et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol 2012; 23: 739-749.
20. Bayes B, Granada ML, Pastor MC, Lauzurica R, Salinas I, Sanmartí A et al. Obesity, adiponectin and inflammation as predictors of new-onset diabetes mellitus after kidney transplantation. Am J Transplant 2007; 7: 416-422.
21. Hjelmesaeth J, Hartmann A, Kofstad J, Stenstrøm J, Leivestad T, Egeland T et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979-983.
22. Woodle ES, First MR, Pirsch J, Shihab F, Gaber AO, Van Veldhuisen P et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564-577.
23. Webster A, Woodroffe RC, Taylor RS, Chapman JR, Craig JC. Tacrolimus versus cyclosporin as primary immunosuppression for kidney transplant recipients. Cochrane Database Syst Rev 2005: CD003961.
24. Busque S, Cantarovich M, Mulgaonkar S, Gaston R, Gaber AO, Mayo PR, Ling S et al. The PROMISE study: a phase 2b multicenter study of voclosporin (ISA247) versus tacrolimus in de novo kidney transplantation. Am J Transplant 2011; 11: 2675-2684.
25. Johnston O, Rose CL, Webster AC, Gill JS. Sirolimus is associated with new-onset diabetes in kidney transplant recipients. J Am Soc Nephrol 2008; 19: 1411-1418.
26. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC. Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 2002; 25: 583-592.
27. Prasad N, Gurjer D, Bhadauria D, Gupta A, Srivastava A, Kaul A et al. Is basiliximab induction, a novel risk factor for new onset diabetes after transplantation for living donor renal allograft recipients? Nephrology (Carlton) 2014; 19: 244-250.
28. Vanrenterghem Y, Bresnahan B, Campistol J, Durrbach A, Grinyó J, Neumayer HH et al. Belatacept-based regimens are associated with improved cardiovascular and metabolic risk factors compared with cyclosporine in kidney transplant recipients (BENEFIT and BENEFIT-EXT studies). Transplantation. 2011; 91: 976-983.
29. Kim YG, Ihm CG, Lee TW, Lee SH, Jeong KH, Moon JY, Chung JH et al. Association of genetic polymorphisms of interleukins with new-onset diabetes after transplantation in renal transplantation. Transplantation 2012; 93: 900-907.
30. Hamer RA, Chow CL, Ong AC, McKane WS. Polycystic kidney disease is a risk factor for new-onset diabetes after transplantation. Transplantation 2007; 83: 36-40.
31. Bayer ND, Cochetti PT, Anil Kumar MS, Teal V, Huan Y, Doria C et al. Association of metabolic syndrome with development of new-onset diabetes after transplantation. Transplantation 2010; 90: 861-866.
32. Kuypers DR, Claes K, Bammens B, Evenepoel P, Vanrenterghem Y. Early clinical assessment of glucose metabolism in renal allograft recipients: diagnosis and prediction of post-transplant diabetes mellitus (PTDM). Nephrol Dial Transplant 2008; 23: 2033-2042.
33. Chakkera HA, Weil EJ, Swanson CM, Dueck AC, Heilman RL, Reddy KS et al. Pretransplant risk score for new-onset diabetes after kidney transplantation. Diabetes Care 2011; 34: 2141-2145.
34. Rodrigo E, Santos L, Piñera C, Millán JC, Quintela ME, Toyos C et al. Prediction at first year of incident new-onset diabetes after kidney transplantation by risk prediction models. Diabetes Care 2012; 35: 471-473.
35. Israni AK, Snyder JJ, Skeans MA, Kasiske BL. PORT Investigators. Clinical diagnosis of metabolic syndrome: predicting new-onset diabetes, coronary heart disease, and allograft failure late after kidney transplant. Transpl Int 2012; 25: 748-757.
36. Sharif A, Baboolal K. Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol 2012; 8: 34-42.
37. Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, Markell MS et al. Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 1998; 65: 380-384.
38. Matas AJ, Gillingham KJ, Humar A, Ibrahim HN, Payne WD, Gruessner RW et al. Post-transplant diabetes mellitus and acute rejection: impact on kidney transplant outcome. Transplantation 2008; 85: 338-343.
39. Tsai JP, Lian JD, Wu SW, Hung TW, Tsai HC, Chang HR. Long-term impact of pretransplant and post-transplant diabetes mellitus on kidney transplant outcomes. World J Surg 2011; 35: 2818-2125.
40. Siraj ES, Abacan C, Chinnappa P, Wojtowicz J, Braun W. Risk factors and outcomes associated with post-transplant diabetes mellitus in kidney transplant recipients. Transplant Proc 2010; 42: 1685-1689.
41. Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM. Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 2001; 15: 89-94.
42. Kuo HT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretransplant diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing (OPTN/UNOS) database. Am J Kidney Dis 2010; 56: 1127-1139.
43. Joss N, Staatz CE, Thomson AH, Jardine AG. Predictors of new onset diabetes after renal transplantation. Clin Transplant 2007; 21: 136-143.
44. Cotovio P, Neves M, Rodrigues L, Alves R, Bastos M, Baptista C et al. New-onset diabetes after transplantation: assessment of risk factors and clinical outcomes. Transplant Proc 2013; 45: 1079-1083.
45. Israni AK, Snyder JJ, Skeans MA, Peng Y, Maclean JR, Weinhandl ED et al. Predicting coronary heart disease after kidney transplantation: Patient Outcomes in Renal Transplantation (PORT) Study. Am J Transplant 2010; 10: 338-353.
46. Leavey SF, McCullough K, Hecking E, Goodkin D, Port FK, Young EW. Body mass index and mortality in 'healthier' as compared with 'sicker' haemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2001; 16: 2386-2394.
47. Painter P, Ward K, Nelson RD. Self-reported physical activity in patients with end stage renal disease. Nephrol Nurs J 2011; 38: 139-147.
48. Sharif A, Moore R, Baboolal K. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008; 85: 353-358.
49. Kamar N, Toupance O, Buchler M, Sandres-Saune K, Izopet J, Durand D et al. Evidence that clearance of hepatitis C virus RNA after alpha-interferon therapy in dialysis patients is sustained after renal transplantation. J Am Soc Nephrol 2003; 14: 2092-2098.
50. Prasad GVR, Kim SJ, Huang M, Nash MM, Zaltzman JS, Fenton SS et al. Reduced Incidence of New-Onset Diabetes Mellitus after Renal Transplantation with 3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Inhibitors (Statins). Am J Transplant 2004; 4: 1897-1903.
51. Werzowa J, Hecking M, Haidinger M, Lechner F, Döller D, Pacini G et al. Vildagliptin and pioglitazone in patients with impaired glucose tolerance after kidney transplantation: a randomized, placebo-controlled clinical trial. Transplantation 2013; 95: 456-462.
52. Oberholzer J, Thielke J, Hatipoglu B, Testa G, Sankary HN, Benedetti E. Immediate conversion from tacrolimus to cyclosporine in the treatment of posttransplantation diabetes mellitus. Transplant Proc 2005; 37: 999-1000.
53. Teutonico A, Schena PF, Di Paolo S. Glucose metabolism in renal transplant recipients: effect of calcineurin inhibitor withdrawal and conversion to sirolimus. J Am Soc Nephrol 2005; 16: 3128-3135.
54. Madsen JC. KDIGO Clinical Practice Guideline for the Care of Kidney Transplant Recipients. Am J Trans 2009; 9: S1-S155.
55. Turk T, Pietruck F, Dolff S, Kribben A, Janssen OE, Mann K et al. Repaglinide in the management of new-onset diabetes mellitus after renal transplantation. Am J Transplant 2006; 6: 842-846.
56. Lane JT, Odegaard DE, Haire CE, Collier DS, Wrenshall LE, Stevens RB et al. Sitagliptin therapy in kidney transplant recipients with new-onset diabetes after transplantation. Transplantation 2011; 92: e56-57.
57. Haidinger M, Werzowa J, Voigt HC, Pleiner J, Stemer G, Hecking M et al. A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation. Trials 2010; 11: 91.
58. Ghisdal L, Van Laecke S, Abramowicz MJ, Vanholder R, Abramowicz D. New-Onset Diabetes After Renal Transplantation: Risk assessment and management. Diabetes Care 2012; 35: 181-188.